sorafenib has been researched along with pki 587 in 4 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (pki 587) | Trials (pki 587) | Recent Studies (post-2010) (pki 587) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 47 | 6 | 46 |
| Protein | Taxonomy | sorafenib (IC50) | pki 587 (IC50) |
|---|---|---|---|
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Homo sapiens (human) | 0.0567 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | 0.0019 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Homo sapiens (human) | 0.0133 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0015 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | 0.016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Angulo, P; Chen, C; Daily, MF; Evers, BM; Gedaly, R; Hundley, J | 1 |
| Angulo, P; Chen, C; Cohen, DA; Daily, MF; Evers, BM; Galuppo, R; Gedaly, R; Hundley, J; Musgrave, Y; Shah, M; Spear, BT | 1 |
| Borg, Å; Cordero, E; Haraldsson, K; Hemann, MT; Kabir, NN; Kazi, JU; Levander, F; Lindblad, O; Macaulay, L; Pietras, K; Puissant, A; Ramos, A; Rönnstrand, L; Stegmaier, K; Sun, J; Vallon-Christersson, J | 1 |
4 other study(ies) available for sorafenib and pki 587
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Drug Synergism; Feedback, Physiological; Furans; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Triazines | 2012 |
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Liver Neoplasms; MAP Kinase Signaling System; Morpholines; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); raf Kinases; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Triazines | 2013 |
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Morpholines; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays | 2016 |